| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,820,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.58 - $25.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
| Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
2,480 |
210,683 |
365,092 |
452,513 |
| Total Sell Value |
$25,523 |
$100,755 |
$167,195 |
$249,561 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
9 |
12 |
17 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kelly John Alexander |
Chief Financial Officer |
• – – |
2024-05-08 |
4 |
A |
$12.00 |
$100,008 |
D/D |
8,334 |
31,014 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2024-05-08 |
4 |
A |
$12.00 |
$9,996 |
D/D |
833 |
6,513 |
|
- |
|
| Amoroso Michael |
President and CEO |
• • – |
2024-05-08 |
4 |
A |
$12.00 |
$100,008 |
D/D |
8,334 |
22,106 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2024-05-08 |
4 |
A |
$12.00 |
$9,996 |
D/D |
833 |
68,446 |
|
- |
|
| Brown Melinda |
|
– • – |
2024-05-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,202 |
4,202 |
|
- |
|
| Germano Geno J |
|
– • – |
2024-05-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,202 |
4,202 |
|
- |
|
| Frankel Stanley |
|
– • – |
2024-05-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,202 |
4,252 |
|
- |
|
| Buehler Kevin |
|
– • – |
2024-05-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,202 |
4,392 |
|
- |
|
| Pire Shari Lisa |
|
– • – |
2024-05-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,202 |
4,202 |
|
- |
|
| Wadsworth Samuel C. |
|
– • – |
2024-05-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,202 |
4,202 |
|
- |
|
| List Alan |
Chief Medical Officer |
• – – |
2024-05-02 |
4 |
AS |
$10.32 |
$2,993 |
D/D |
(290) |
4,488 |
|
14% |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2024-05-02 |
4 |
S |
$10.32 |
$1,589 |
D/D |
(154) |
67,613 |
|
-11% |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2024-05-02 |
4 |
AS |
$10.32 |
$2,807 |
D/D |
(272) |
5,680 |
|
14% |
|
| Amoroso Michael |
President and CEO |
• • – |
2024-05-02 |
4 |
AS |
$10.32 |
$15,748 |
D/D |
(1,526) |
13,772 |
|
14% |
|
| List Alan |
Chief Medical Officer |
• – – |
2024-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
982 |
4,778 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2024-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
519 |
67,767 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2024-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
918 |
5,952 |
|
- |
|
| Amoroso Michael |
President and CEO |
• • – |
2024-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,417 |
15,298 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2024-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,702 |
22,680 |
|
- |
|
| List Alan |
Chief Medical Officer |
• – – |
2024-04-30 |
4 |
AS |
$10.03 |
$2,386 |
D/D |
(238) |
3,796 |
|
19% |
|
| List Alan |
Chief Medical Officer |
• – – |
2024-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
868 |
4,034 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2024-02-29 |
4 |
A |
$12.42 |
$12,495 |
D/D |
1,006 |
67,248 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2024-02-29 |
4 |
A |
$18.50 |
$9,361 |
D/D |
506 |
20,978 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2024-01-23 |
4 |
S |
$0.37 |
$10,360 |
D/D |
(28,000) |
1,987,269 |
|
-9% |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2024-01-22 |
4 |
AS |
$0.36 |
$7,663 |
D/D |
(21,287) |
151,028 |
|
11% |
|
179 Records found
|
|
Page 1 of 8 |
|
|
0.42 (3.51%) 
